193 related articles for article (PubMed ID: 23860970)
1. Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety.
Mitka M
JAMA; 2013 Jul; 310(3):246-7. PubMed ID: 23860970
[No Abstract] [Full Text] [Related]
2. Diabetes drug safety update: Avandia and your heart.
Johns Hopkins Med Lett Health After 50; 2010 Jun; 22(4):1-2, 7. PubMed ID: 20572316
[No Abstract] [Full Text] [Related]
3. FDA advisers favor easing rosiglitazone restrictions.
Traynor K
Am J Health Syst Pharm; 2013 Jul; 70(14):1184-5. PubMed ID: 23820451
[No Abstract] [Full Text] [Related]
4. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
Hiatt WR; Kaul S; Smith RJ
N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603
[No Abstract] [Full Text] [Related]
5. Revisiting the rosiglitazone story--lessons learned.
Rosen CJ
N Engl J Med; 2010 Aug; 363(9):803-6. PubMed ID: 20660395
[No Abstract] [Full Text] [Related]
6. FDA panel advises easing restrictions on rosiglitazone.
Tucker ME
BMJ; 2013 Jun; 346():f3769. PubMed ID: 23752055
[No Abstract] [Full Text] [Related]
7. The Avandia debate: an unhappy conclusion.
Bloomgarden Z; Handelsman Y
J Diabetes; 2010 Dec; 2(4):221-2. PubMed ID: 20923505
[No Abstract] [Full Text] [Related]
8. [Doubts as to the cardiovascular safety of rosiglitazone].
Hoekstra JB; Bossuyt PM; de Vries JH
Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1449-50. PubMed ID: 17633972
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone and cardiovascular risk.
Psaty BM; Furberg CD
N Engl J Med; 2007 Jun; 356(24):2522-4. PubMed ID: 17517854
[No Abstract] [Full Text] [Related]
10. In brief: rosiglitazone (Avandia) unbound.
Med Lett Drugs Ther; 2014 Feb; 56(1435):12. PubMed ID: 24662977
[No Abstract] [Full Text] [Related]
11. The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
Rosen CJ
N Engl J Med; 2007 Aug; 357(9):844-6. PubMed ID: 17687124
[No Abstract] [Full Text] [Related]
12. Cardiovascular safety of rosiglitazone.
Krall RL
Lancet; 2007 Jun; 369(9578):1995-1996. PubMed ID: 17574083
[No Abstract] [Full Text] [Related]
13. [Doubts as to the cardiovascular safety of rosiglitazone].
Wolffenbuttel BH
Ned Tijdschr Geneeskd; 2007 Oct; 151(40):2236-7; author reply 2237. PubMed ID: 17969577
[No Abstract] [Full Text] [Related]
14. Rosiglitazone, marketing, and medical science.
Moynihan R
BMJ; 2010 Apr; 340():c1848. PubMed ID: 20375091
[No Abstract] [Full Text] [Related]
15. Rosiglitazone and cardiovascular disease: a diabetologist's perspective.
Grant PJ
Diab Vasc Dis Res; 2007 Jun; 4(2):75-6. PubMed ID: 17654437
[No Abstract] [Full Text] [Related]
16. [What about the controversy regarding rosiglitazone].
Scheen AJ; De Flines J; Paquot N
Rev Med Liege; 2007 Sep; 62(9):560-5. PubMed ID: 17966792
[TBL] [Abstract][Full Text] [Related]
17. The Yin and the Yang of CV risks in patients with diabetes.
Dangi-Garimella S
Am J Manag Care; 2014 May; 20(8 Spec No.):E6. PubMed ID: 25617925
[No Abstract] [Full Text] [Related]
18. Editorial: What have we lost in the wake of the rosiglitazone controversy?
Zarich SW; Nesto RW
Endocr Pract; 2009 Apr; 15(3):273-4. PubMed ID: 19364699
[No Abstract] [Full Text] [Related]
19. Rosiglitazone and the FDA.
Krall RL
N Engl J Med; 2007 Oct; 357(17):1776-7; author reply 1777. PubMed ID: 17969232
[No Abstract] [Full Text] [Related]
20. The value equation for rosiglitazone and pioglitazone in older persons.
Zarowitz BJ
Geriatr Nurs; 2008; 29(1):9-11. PubMed ID: 18267172
[No Abstract] [Full Text] [Related]
[Next] [New Search]
